Aktieanalys

Cantargia: Closing in on a Licensing Deal? - Redeye

{newsItem.title}

Redeye Publicerad: 30 Mar 2022 10:25

Redeye updates its view on Cantargia following a period that has brought promising trial results and the initiation of several new clinical projects. We adjust our estimates and valuation based on new timelines and an updated WACC.

Länk till analysen i sin helhet: https://www.redeye.se/research/837273/closing-in-on-a-licensing-deal?utm_source=finwire&utm_medium=RSS

Nyheter om Cantargia

Läses av andra just nu

Om aktien Cantargia

Senaste nytt